<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2016-05-20" updated="2020-01-02">
  <drugbank-id primary="true">DB11597</drugbank-id>
  <name>Human Rho(D) immune globulin</name>
  <description>Human Rho(D) immune globulin is a medicine given by intramuscular or intravenous injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). Rho (D) immune globulin is available as a sterile, lyophilized or liquid gamma globulin (IgG) fraction containing antibodies to the Rh0 (D) antigen (D antigen) under the name Rhophylac (IM/IV). Immune globullin was purified via ion-exchange chromatography method and prepared from pools of human plasma, where the donors are Rho (D)-negative donors who have been immunized with Rho(D)-positive RBCs. It was approved by FDA as treatment for suppression of rhesus (Rh) isoimmunization or chronic immune thrombocytopenic purpura (ITP) in adults.</description>
  <cas-number/>
  <unii>48W7181FLP</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A19517</ref-id>
        <pubmed-id>19707396</pubmed-id>
        <citation>Cheung E, Liebman HA: Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia. Biologics. 2009;3:57-62. Epub 2009 Jul 13.</citation>
      </article>
      <article>
        <ref-id>A19519</ref-id>
        <pubmed-id>1850307</pubmed-id>
        <citation>Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM: Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood. 1991 May 1;77(9):1884-93.</citation>
      </article>
      <article>
        <ref-id>A19521</ref-id>
        <pubmed-id>10796088</pubmed-id>
        <citation>Crowther CA, Keirse MJ: Anti-D administration in pregnancy for preventing rhesus alloimmunisation. Cochrane Database Syst Rev. 2000;(2):CD000020.</citation>
      </article>
      <article>
        <ref-id>A19522</ref-id>
        <pubmed-id>20008198</pubmed-id>
        <citation>Brinc D, Lazarus AH: Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. Hematology Am Soc Hematol Educ Program. 2009:185-91. doi: 10.1182/asheducation-2009.1.185.</citation>
      </article>
      <article>
        <ref-id>A19523</ref-id>
        <pubmed-id>17897303</pubmed-id>
        <citation>Brinc D, Le-Tien H, Crow AR, Freedman J, Lazarus AH: IgG-mediated immunosuppression is not dependent on erythrocyte clearance or immunological evasion: implications for the mechanism of action of anti-D in the prevention of haemolytic disease of the newborn? Br J Haematol. 2007 Oct;139(2):275-9.</citation>
      </article>
      <article>
        <ref-id>A19527</ref-id>
        <pubmed-id>12504934</pubmed-id>
        <citation>Bichler J, Schondorfer G, Pabst G, Andresen I: Pharmacokinetics of anti-D IgG in pregnant RhD-negative women. BJOG. 2003 Jan;110(1):39-45.</citation>
      </article>
      <article>
        <ref-id>A19529</ref-id>
        <pubmed-id>8450718</pubmed-id>
        <citation>Poortmans JR, Jeanloz RW: Urinary excretion of immunoglobulins and their subunits in human subjects before and after exercise. Med Sci Sports Exerc. 1993 Feb;25(2):171-8.</citation>
      </article>
      <article>
        <ref-id>A19530</ref-id>
        <pubmed-id>1266624</pubmed-id>
        <citation>Haneberg B, Endresen C: Fragments of immunoglobulins in human faeces. Acta Pathol Microbiol Scand C. 1976 Feb;84(1):31-6.</citation>
      </article>
      <article>
        <ref-id>A19531</ref-id>
        <pubmed-id>813931</pubmed-id>
        <citation>Haneberg B, Aarskog D: Human faecal immunoglobulins in healthy infants and children, and in some with diseases affecting the intestinal tract or the immune system. Clin Exp Immunol. 1975 Nov;22(2):210-22.</citation>
      </article>
      <article>
        <ref-id>A19532</ref-id>
        <pubmed-id>1225487</pubmed-id>
        <citation>Arend WP, Silverblatt FJ: Serum disappearance and catabolism of homologous immunoglobulin fragments in rats. Clin Exp Immunol. 1975 Dec;22(3):502-13.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L803</ref-id>
        <title>Rhophylac Summary of Basis for Approval</title>
        <url>https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM119475.pdf</url>
      </link>
      <link>
        <ref-id>L804</ref-id>
        <title>WinRho Product information</title>
        <url>https://www.fda.gov/downloads/ApprovedProducts/UCM198717.pdf</url>
      </link>
      <link>
        <ref-id>L805</ref-id>
        <title>RhoGam (Rho(D) Immune Globulin intramuscular injection) product information</title>
        <url>http://www.ctint.org/inserts/RhoGam_insert.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Indicated for suppression of rhesus (Rh) isoimmunization in nonsensitized Rho (D)-negative women with an Rh-incompatible pregnancy, or in Rho (D)-negative individuals transfused with Rh0(D)-positive red blood cells (RBCs) or blood components containing Rh0(D)-positive RBCs. Also indicated in Rh0(D)-positive, non-splenectomized adult patients with chronic immune thrombocytopenic purpura (ITP) to raise platelet counts.</indication>
  <pharmacodynamics>15000 international unit (IU) contains sufficient anti-Rho (D) to effectively suppress the immunizing potential of approximately 17mL of Rho (D) (D-positive) red blood cells [L804]. Human Rho(D) immune globulin therapy prevents immunization to Rho (D)-positive red blood cells (RBC) by inducing antibody-mediated immunosuppression (AMIS) effectively clearing Rho-positive RBCs by rapidly binding to them. This prevents Rho-negative mothers to produce alloantibodies to paternally inherited RhD antigen expressed on fetal erythrocytes and cause haemolytic diseases of the newborn. &#13;
Rho immune globulin increase platelet counts and reduce bleeding in Rho-positive patients with ITP by inhibiting autoantibody-mediated platelet clearance. </pharmacodynamics>
  <mechanism-of-action>The mechanism of action of Rho(D) immune globulin therapy is unclear. It is suggested that Rho immune globulin predominantly prevents the antibody response during incompatible pregnancy by accelerating the phagocytosis of RBC's and clearance from the circulation before the recognition by the immune system. IgG-opsonized RBCs may interact with activating IgG receptors (FcγRs) on effector cells and elicit phagocytosis via mononuclear phagocytic system, primarily by macrophages. IgG may also stimulate complement activation on the RBC surface, followed by RBC lysis or complement receptor-mediated phagocytosis but to smaller extent [A19522]. Rho-specific IgG may inhibit the late stages of B cell activation by being internalized with Rho antigen by B cells, which alters the antigen processing and presentation. In response to the IgG-antigen complex formation, the immune globulin enhances the presentation of specific peptides and proliferation of epitope-specific T cells [A19522]. &#13;
Therapeutic efficacy of Rho (D) immune globulin in chronic immune thrombocytopenic purpura (ITP) may be explained by FcR blockade as well as the increase in the platelet count by substituting antibody-coated RBCs for antibodycoated platelets [A19519]. In vitro studies of cytokine expression in human monocytes and granulocytes exposed to anti-D coated red blood cells have demonstrated enhanced secretion of interleukin 1 receptor antagonist resulting in down-regulation of FcγR mediated phagocytosis. Murine models show that RBC-specific antibodies can increase platelet counts by down-regulating FcγRIIIa on splenic macrophage, which is an opposing effect as predicted in intravenous Rho IgG [A19521]. </mechanism-of-action>
  <toxicity>Most serious adverse reactions in patients with ITP include intravascular hemolysis, anemia, acute renal insufficiency, and death. In patients treated for Rh isoimmunization suppression, common adverse effects include nausea, dizziness, headache, pain at injection site and malaise. Common adverse effects in patients with ITP include chills, pyrexia, mild extravascular hemolysis and headache.</toxicity>
  <metabolism>Rho (D) immune globulin is expected to undergo nonspecific catabolism. </metabolism>
  <absorption>In patients undergoing therapy for Rh isoimmunization suppression, Rho(D) immune globulin titers were detected in all women up to at least 9 weeks following either intravenous or intramuscular administration. Following intravenous administration of a single 1500 IU (300 mcg) dose, peak serum levels of Rh0(D) immune globulin ranged from 62 to 84 ng/mL after first day. The levels ranged from 7 to 46 ng/mL and were achieved between 2 and 7 days following intramuscular injection. The absolute bioavailability achieved following IM administration is 69%. </absorption>
  <half-life>The half life is 16 ± 4 days following IV administration and 18 ± 5 days following IM administration.</half-life>
  <protein-binding/>
  <route-of-elimination>Human immune globulin and the fragments can be detected in feces and urine. </route-of-elimination>
  <volume-of-distribution>A single dose of 300ug Rho(D) Immune Globulin through intramuscular injection displays a Vd of 8.59L [L805]. </volume-of-distribution>
  <clearance>Mean systemic clearance following IV administration is 0.20 ±0.03 mL/min. Mean apparent clearance following IM administration is 0.29 ± 0.12 mL/min.</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Anti-D (RH) immunoglobulin (human)</synonym>
    <synonym language="english" coder="">Anti-D immunoglobulin</synonym>
    <synonym language="english" coder="">Anti-D immunoglobulins</synonym>
    <synonym language="english" coder="">Human anti-D immunoglobulin</synonym>
    <synonym language="english" coder="">IGG, Rho (D)</synonym>
    <synonym language="english" coder="">Immunoglobulin human anti-RH</synonym>
    <synonym language="english" coder="">Rh0(D) Immune Globulin Intravenous (Human)</synonym>
    <synonym language="english" coder="">Rho (D) immune globulin,human</synonym>
    <synonym language="english" coder="">Rho D immune globulin human</synonym>
    <synonym language="english" coder="">Rho(D) immune globulin (human)</synonym>
    <synonym language="english" coder="">Rho(D) immune globulin human</synonym>
    <synonym language="english" coder="">Rho(D) immune globulin IM human</synonym>
  </synonyms>
  <products>
    <product>
      <name>Hyp Rho D Inj 16.5%</name>
      <labeller>Cutter Med &amp; Biol, Division Of Miles Canada Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00083267</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on>1998-09-25</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Hyperrho S/d Full Dose</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13533-631</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1500 [iU]/1</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA101141</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hyperrho S/d Mini-dose</name>
      <labeller>GRIFOLS USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13533-661</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>250 [iU]/1</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA101141</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MICRhoGAM Ultra-Filtered PLUS</name>
      <labeller>Kedrion Melville Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0562-7806</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 ug/1</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA103777</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>RhoGAM Ultra-Filtered PLUS</name>
      <labeller>Kedrion Melville Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0562-7805</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 ug/1</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA103777</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rhophylac</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-300</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1500 [iU]/2mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>BLA125070</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Winrho Sd Kit Inj</name>
      <labeller>Rh Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02022842</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Winrho Sd Kit Inj.</name>
      <labeller>Rh Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02022834</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>WinRho SDF</name>
      <labeller>Saol Therapeutics Research Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02302586</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2500 unit</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>WinRho SDF</name>
      <labeller>Saol Therapeutics Research Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02302578</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1500 unit</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>WinRho SDF</name>
      <labeller>Aptevo Biotherapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230397</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-01-28</started-marketing-on>
      <ended-marketing-on>2016-07-15</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength>5000 unit</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>WinRho SDF</name>
      <labeller>Saol Therapeutics Research Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02302551</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>600 unit</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>WinRho SDF</name>
      <labeller>Aptevo Biotherapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02217449</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-28</started-marketing-on>
      <ended-marketing-on>2016-07-15</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength>1500 unit</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>WinRho SDF</name>
      <labeller>Saol Therapeutics Research Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02302594</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>5000 unit</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>WinRho SDF</name>
      <labeller>Aptevo Biotherapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02217430</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-01-10</started-marketing-on>
      <ended-marketing-on>2016-07-15</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength>600 unit</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>WinRho SDF</name>
      <labeller>Saol Therapeutics Research Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02302608</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>15000 unit</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Winrho Sd Kit Inj</name>
      <ingredients>Human Rho(D) immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>Winrho Sd Kit Inj.</name>
      <ingredients>Human Rho(D) immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>Rhophylac</name>
      <ingredients>Human Rho(D) immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>Hyperrho S/d Full Dose</name>
      <ingredients>Human Rho(D) immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>Hyperrho S/d Mini-dose</name>
      <ingredients>Human Rho(D) immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>RhoGAM Ultra-Filtered PLUS</name>
      <ingredients>Human Rho(D) immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>MICRhoGAM Ultra-Filtered PLUS</name>
      <ingredients>Human Rho(D) immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>WinRho SDF</name>
      <ingredients>Human Rho(D) immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>WinRho SDF</name>
      <ingredients>Human Rho(D) immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>WinRho SDF</name>
      <ingredients>Human Rho(D) immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>Hyp Rho D Inj 16.5%</name>
      <ingredients>Human Rho(D) immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>WinRho SDF</name>
      <ingredients>Human Rho(D) immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>WinRho SDF</name>
      <ingredients>Human Rho(D) immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>WinRho SDF</name>
      <ingredients>Human Rho(D) immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>WinRho SDF</name>
      <ingredients>Human Rho(D) immune globulin</ingredients>
    </mixture>
    <mixture>
      <name>WinRho SDF</name>
      <ingredients>Human Rho(D) immune globulin</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Endogenous Antigen Neutralization</category>
      <mesh-id/>
    </category>
    <category>
      <category>Human Immunoglobulin G</category>
      <mesh-id/>
    </category>
    <category>
      <category>Passively Acquired Immunity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Serum</category>
      <mesh-id>D044967</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular</route>
      <strength>1500 [iU]/1</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular</route>
      <strength>250 [iU]/1</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular</route>
      <strength>50 ug/1</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular</route>
      <strength>300 ug/1</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>1500 [iU]/2mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intramuscular; Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intramuscular; Intravenous</route>
      <strength>1500 unit</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intramuscular; Intravenous</route>
      <strength>5000 unit</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intramuscular; Intravenous</route>
      <strength>600 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>1500 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>15000 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>2500 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>5000 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>600 unit</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes>
    <ahfs-code>80:04.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB11597.pdf?1496764853</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7768</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7771</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>22927</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347911208</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Rho(D)_immune_globulin</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0002389</id>
      <name>Rhesus blood group D antigen</name>
      <organism>Humans</organism>
      <actions>
        <action>antibody</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="A6PZ59" source="TrEMBL">
        <name>Rhesus blood group D antigen</name>
        <general-function>Ammonium transmembrane transporter activity</general-function>
        <specific-function/>
        <gene-name>RHD</gene-name>
        <locus>1p36.11</locus>
        <cellular-location/>
        <transmembrane-regions>12-31
43-65
77-94
139-160
172-191
203-220
240-258
295-312
332-349
361-388</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.22</theoretical-pi>
        <molecular-weight>45275.06</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AM491130</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>150246790</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>A6PZ59</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>A6PZ59_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021987|Rhesus blood group D antigen
MSSKYPRSVRRCLPLWALTLEAALILLFYFFTHYDASLEDQKGLVASYQVGQDLTVMAAI
GLGFLTSSFRRHSWSSVAFNLFMLALGVQWAILLDGFLSQFPSGKVVITLFSIRLATMSA
LSVLISVDAVLGKVNLAQLVVMVLVEVTALGNLRMVISNIFNTDYHMNLRHFYVFAAYFG
LTVAWCLPKPLPKGTEDNDQRATIPSLSAMLGALFLWMFWPSFNSALLRSPIERKNAVFN
TYYAVAVSVVTAISGSSLAHPQGKISKTYVHSAVLAGGVAVGTSCHLIPSPWLAMVLGLV
AGLISVGGAKYLPGCCNRVLGIPHSSIMGYNFSLLGLLGEIIYIVLLVLDTVGAGNGMIG
FQVLLSIGELSLAIVIALTSGLLTGLLLNLKIWKAPHEAKYFDDQVFWKFPHLAVGF</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams>
          <pfam>
            <identifier>PF00909</identifier>
            <name>Ammonium_transp</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ammonium transmembrane transporter activity</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>